Mol Cell Biochem 2002, 234–235:301–308.PubMedCrossRef 47. Ninomiya M, Kajiguchi T, Yamamoto K, Kinoshita T, Emi N, Naoe T: Increased oxidative DNA products in patients with acutepromyelocyticleukemia during arsenic therapy. Haematologica 2006, 91:1571–1572.PubMed 48. Jia P, Chen G, Huang X, Cai X, Yang J, Wang L, Zhou Y, Shen Y, Zhou L, Yu Y, Chen S, Zhang X, Wang Z: Arsenic trioxide induces multiple check details myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspace-3. Chin Med J (Engl) 2001, 114:19–24. 49. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC: Effect of arsenic trioxide on viability, proliferation,

and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999, 27:845–852.PubMedCrossRef 50. Rousselot

P, Labaume S, Marolleau JP, Larghero J, Noguera MK, Brouet JC, Fermand JP: Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cellsfrom myeloma patients. Cancer Res 1999, 59:1041–1048.PubMed 51. Carvalho PS, Catian R, Moukha S, Matias WG, Creppy EE: Comparative study of domoic acid and okadaic acid induced -chromosomal abnormalities in the CACO-2 Cell Line. Int J Environ Res Public Health 2006, 3:4–10.PubMedCentralPubMedCrossRef Competing interests selleck kinase inhibitor The authors declare that they have no competing interests. Authors’ contributions SK and PBT conceived, designed and implemented the study, and drafted the manuscript.CGY participated in the implementation of Dinaciclib research activities. All authors read and approved the final draft of the manuscript.”
“Introduction

The clinical problem Endometrial carcinoma (EC) is the second most frequent gynecological malignancy in women with 49,560 cases reported and 8,190 deaths from this disease in the US in 2013 [1]. It has also recently been reported that more than 1,900 women die from EC each year in the UK (http://​www.​cancerresearchuk​.​org). The number of reported cases of EC makes it the leading cause of cancer-related deaths across the globe [2–4]. Major EC-related symptoms include dysfunctional 4��8C uterine bleeding, hypermenorrhea, irregular menstruation, and sterility [5]. The two main types of EC are estrogen-dependent type I and estrogen-independent type II carcinomas [6]. Type I EC is the most prevalent type – accounting for 75%–85% of all ECs – and occurs primarily in postmenopausal women [7]. However, approximately 25% of women with EC are pre-menopausal and 5% of cases are diagnosed at younger than 40 years of age [2]. Despite a growing understanding of the mechanisms of tumorigenesis, complete knowledge of the exact causes of EC is still lacking. Due to the limitations of current therapeutic tools, surgical procedures are still the most effective first-line treatments for the early stage of this disease [8–12]. A significant drawback to surgical interventions, however, is that they preclude any further fertility in women with EC.